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Background: Interleukin (IL)-17A plays a pivotal role in the pathogenesis of rheumatoid arthritis (RA).
The expression of IL-17A in synovial mast cells (MCs) in RA and osteoarthritis (OA) has been reported, but
the frequencies of IL-17A expression in synovial MCs have varied. The aim of this study was to investigate
whether IL-17A expression is upregulated in human synovial MCs in RA and to elucidate the mechanism
of IL-17A expression in synovial MCs.
Methods: Synovial tissues were obtained from patients with RA or OA undergoing joint replacement
surgery, and synovial MCs were enzymatically dispersed. Synovium-derived cultured MCs were gener-
ated by culturing synovial cells with stem cell factor. IL-17A expression was investigated using immu-
noﬂuorescence in synovial tissues. IL-17A mRNA expression and its production from MCs were examined
using RT-PCR and ELISA, respectively.
Results: The number of IL-17A-positive (þ) synovial MCs and the percentage of IL-17AþMCs among all the
IL-17Aþ cells from RA patients were not signiﬁcantly increased compared with those from OA subjects.
The synovium-derived cultured MCs spontaneously released small amounts of IL-17A. Neither IgE- nor
IgG-dependent stimulation increased IL-17A production from the MCs. IL-33, tumor necrosis factor-a,
C5a, lipopolysaccharide or IL-23 plus IL-1b did not affect IL-17A production in MCs.
Conclusions: The synovial MCs are not a main source of IL-17A in RA.
Copyright © 2016, Japanese Society of Allergology. Production and hosting by Elsevier B.V. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Rheumatoid arthritis (RA) is a chronic systemic inﬂammatory
disease characterized by the immune cell-mediated destruction of
the joint architecture. Proinﬂammatory cytokines, such as tumor
necrosis factor-a (TNF-a), interleulin-1b (IL-1b), IL-6, and IL-17A,y Project Team, Division of
n University School of Medi-
-8610, Japan.
p (Y. Okayama).
ety of Allergology.
rgology. Production and hosting by Elsehave been assigned pivotal roles in the destruction of the joint ar-
chitecture in patients with RA.1 In arthritis model mice, deﬁciency
or blockade of IL-17A leads to the suppression of arthritis.2e4 IL-17A
induces the production of proinﬂammatory cytokines and chemo-
kines in synovial ﬁbroblasts and macrophages, especially in syn-
ergy with other proinﬂammatory cytokines such as TNF-a, and IL-
1b.5,6 IL-17A also stimulates the production of matrix metal pro-
teases by rheumatoid synoviocytes7 and induces differentiation to
osteoclasts via the stimulation of receptor activator of nuclear
factor kB ligand expression on osteoblasts.8 High levels of IL-17A in
synovial ﬂuid and blood are associated with disease severity in
RA.9,10 Therefore IL-17A promotes both inﬂammation and bonevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
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including Th17 cells, gd T cells, natural killer T cells, natural killer
cells, macrophages, neutrophils, eosinophils andmast cells.1 Higher
expression levels of IL-17A in synovial mast cells (MCs) from pa-
tients with RA have been reported.11 On the other hand, van
Baarsen et al. reported that synovial MCs were occasionally positive
for IL-17A.12 Hueber et al.11 reported that human cord-blood
derived cultured MCs produced IL-17A upon stimulation with
TNF-a, IgG complexes, C5a and lipopolysaccharide (LPS). However,
the mechanisms responsible for the upregulation of IL-17A in MCs
have not been well identiﬁed.
In patients with RA, the number of degranulated MCs is
increased in synovial tissue and is correlated with the disease ac-
tivity.13,14 The amounts of histamine and tryptase in synovial ﬂuids
are increased in these patients, suggesting that the activation of
MCs may be involved in the pathogenesis of RA.13,14 We have
recently reported that aggregated IgG activates human synovial
MCs through FcgRI and FcgRII15,16 and that IL-33 synergistically
enhances aggregated IgG-induced TNF-a and IL-8 production in
cultured human synovium-derived MCs.15 Therefore, we hypothe-
sized that (1) synovial MCs upregulate IL-17A expression following
the aggregation of FcgRI or Fc 3RI; and (2) IL-33 affects IL-17A pro-
duction in synovial MCs.
Methods
Ethical considerations
The study was approved by the Ethics Committees of Nihon
University School of Medicine (approved number, RK-100115-4 and
RK-160112-01, 02), and all the subjects provided written informed
consent in accordance with the Helsinki Declaration of the World
Medical Association.
Reagents
The following antibodies (Abs) were purchased from the indi-
cated sources: human IgE (Calbiochem, San Diego, CA, USA); goat
anti-human IL-17A polyclonal Ab (R&D Systems, Minneapolis, MN,
USA); anti-human tryptase monoclonal (m) Ab (clone AA1; Dako-
Cytomation Inc., Carpinteria, CA, USA); anti-Fc 3RIa mAb (clone
CRA1; eBioscience, San Diego, CA, USA); anti-human IgE Ab
(DakoCytomation Inc.); and F(ab0)2 fragments of anti-human FcgRI
(clone 10.1; ID Labs Inc., London, ON, Canada).
Generation of synovium-derived cultured MCs
Cultured human synovium-derived MCs were generated as
described previously.15,16 Brieﬂy, fresh samples of synovial tissues
were obtained after total knee arthroplasty procedure performed at
Nihon University, after receiving informed consent. Synovial cells
were enzymatically dispersed and centrifuged by density-gradient
consisting of 22.5% HistoDenz solution (SigmaeAldrich, St. Louis,
MO, USA) and lymphocyte separation medium (LSM: Organon
Teknika, Durham, NC, USA). The cells at the LSM interface and the
pellet fraction were collected and washed. The cells were then
cultured in serum-free Iscove's methylcellulose medium (Stem Cell
Technologies Inc., Vancouver, BC, Canada) and Iscove's modiﬁed
Dulbecco's medium (IMDM) supplemented with 200 ng/ml of re-
combinant human SCF (rhSCF) (PeproTech, Rocky Hill, NJ, USA) and
50 ng/ml of rhIL-6 (PeproTech). On day 42, methylcellulose was
dissolved in PBS, and the cells were resuspended and cultured in
IMDM containing 0.1% BSA, 100 ng/ml of rhSCF and 50 ng/ml of
rhIL-6.Confocal microscopic analysis
We studied 6 RA patients (median, 74.0 years old) and 6 OA
patients (median, 78.5 years old). The characteristics of the pa-
tients with RA and OA are summarized in Table 1. Patients with
RA were treated with methotrexate, prednisolone, disease-
modifying anti-rheumatic drugs, non-steroidal anti-inﬂamma-
tory drugs, or biological drugs. Patients with RA underwent blood
tests, which included C-reactive protein and anti-cyclic citrulli-
nated peptide Ab. The fresh samples of synovial tissues were
obtained after total knee arthroplasty procedures performed at
Nihon University, after receiving informed consent. Frozen sy-
novial tissue sections (4 mm) were prepared using a cryostat and
were ﬁxed using 4% paraformaldehyde. The sections were then
blocked using 2% non-fat skim milk in PBS for 1 h at 37 C, then
incubated with Alexa Fluor® 488-conjugated anti-human tryptase
mAb, or Alexa Fluor® 555-conjugated anti-human IL-17A Ab
overnight at 4 C. For a negative control, Alexa Fluor® 488-
conjugated mouse IgG1 and Alexa Fluor® 555-conjugated goat
IgG were used in the experiment. The sections and cultured
synovium-derived MCs were mounted using ProLong® Gold
Antifade Reagent with DAPI (Invitrogen, Carlsbad, CA, USA).
Model FV1000 confocal laser scanning microscopes (Olympus,
Tokyo, Japan) were used. All the immunostained sections were
evaluated by two observers who were blinded to the clinical data
of the patients.
RNA isolation and RT-PCR
Total RNA was isolated from the cultured synovium-derived
MCs, and real-time quantitative RT-PCR was performed as
described previously.16 The human gene-speciﬁc primer and probe
sets for IL-17A and GAPDH were designed using the Assay-on-
Demand service (Applied Biosystems, Tokyo, Japan).
Preparation of aggregated IgG
Aggregated IgG was prepared as described previously.16 Brieﬂy,
aggregated IgG was prepared by heating human IgG (Jackson Im-
mune Laboratory, West Grove, PA, USA) at 63 C for 1 h. The large
aggregates were removed by centrifugation at 10,000 g for
30 min. Aggregated IgG used for the experiments were present in
the supernatant.
MC activation
MCs were suspended in IMDM containing 0.1% BSA, 200 ng/ml
of rhSCF, and 50 ng/ml of rhIL-6 (referred to as MC medium). The
number of MCs used for the experiments was adjusted to
1  105 cells/100 ml. For the aggregation of Fc 3RI, MCs were sensi-
tized with 0.5 mg/ml of human IgE for 30 min at 37 C. The cells
were washed once and resuspended in MC medium. The IgE-
sensitized MCs were stimulated with anti-human IgE for 30 min
or 6 h for the IL-17A assays. For the aggregation of FcgRI, the MCs
were incubated with 1 mg/ml of F(ab0)2 fragments of anti-human
FcgRI (F(ab0)2aFcgRI, clone 10.1), or mouse F(ab0)2 fragments of
IgG1 (F(ab0)2mIgG1; Jackson Immune Laboratory) for 30 min at
37 C. The cells were washed once and were resuspended in MC
medium. FcgRI was cross-linked by the incubation of the MCs with
the indicated concentrations of goat F(ab0)2 fragments of anti-
mouse F(ab0)2 fragments of IgG (gF(ab0)2amF(ab0)2; Jackson Im-
mune Laboratory) for 6 h. The MCs were also incubated with
monomeric IgG, aggregated IgG, or rhIL-33 (R&D Systems Inc.) for
6 h. In some experiments, the MCs were stimulated with anti-
Fc 3RIa (clone CRA1), monomeric IgG, or aggregated IgG in the
Table 1
Characteristics of the patients with OA and RA patients.
Patient# Sex Age Dates of operation
(month/day/year)
Onset (year) WBC (/mm3) CRP (mg/dl) Anti-CCP
Ab (U/ml)
MMP3
(ng/ml)
RF (mg/dl) Treatment
OA1 F 80 6/6/2012 2011 6000 0.1 n.d n.d n.d NSAIDs
OA2 M 77 5/24/2012 2011 6300 0.1 n.d n.d n.d NSAIDs
OA3 F 82 6/26/2012 2002 6400 0.23 n.d n.d n.d NSAIDs
OA4 F 76 5/7/2015 2014 7800 0.1 n.d n.d n.d NSAIDs
OA5 F 83 5/13/2015 2014 6200 0.1 n.d n.d n.d NSAIDs
OA6 M 72 5/12/2015 2010 2700 0.13 n.d n.d n.d NSAIDs
RA1 F 69 9/12/2012 2001 7000 0.51 <0.6 342.8 n.d MTX þ anti-TNF-a þ PSL
RA2 F 73 6/20/2012 2012 7900 15.8 322 1490.5 15.2 MTX þ anti-TNF-a
RA3 F 74 8/6/2015 2010 4000 0.10 0.6 n.d 5.3 DMART þ NSAIDs
RA4 F 74 8/4/2015 2012 5700 0.59 36.4 256.5 11.1 MTX þ PSL þ NSAIDs
RA5 F 78 6/8/2015 2014 8000 3.78 727 386.7 n.d MTX
RA6 F 76 7/9/2015 2014 4600 0.43 20.7 133.3 15.8 MTX þ PSL
anti-CCP Ab, cyclic citrullinated peptide antibody; anti-TNF-a, anti-tumor necrosis factor therapy; CRP, C-reactive protein; DMART, disease modifying antirheumatic drug; F,
female; M, male; MMP3, matrix metallopeptidase 3; MTX, methotrexate; n.d, not done; NSAIDs, non-steroidal anti-Inﬂammatory drugs; OA, osteoarthritis; PSL, prednisolone;
RA, rheumatoid arthritis; RF, rheumatoid factor; WBC, white blood cells.
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incubated with TNF-a (R&D Systems Inc.), C5a (SigmaeAldrich),
LPS (SigmaeAldrich), or IL-23 (R&D Systems Inc.) plus IL-b (R&D
Systems Inc.) for 24 h. Independent experiments were performed
using different donors.Fig. 1. Expression of IL-17A in synovial MCs from OA patients and from RA patients. Represen
RA patient (B). Immunochemical staining of synovia with anti-tryptase mAb (green, a) and a
(blue). The white arrow heads indicate tryptase-IL-17A double-positive cells. Bar ¼ 10 mm. (C
IgG1 and goat IgG. The results are representative of separate analyses using 6 patients withMediator assays
Human IL-17A and IL-8 were measured with ELISA kits pur-
chased from BioLegend Inc. (San Diego, CA, USA) and from BD
Biosciences, respectively. The minimum detectable concentrationtative images of IL-17AþMCs (tryptaseþ cells) in synovia from an OA patient (A) and an
nti-IL-17A (red, b) Ab, and a merged image (yellow, c). The cells were stained with DAPI
) As negative controls, a synovium sample from an OA patient was stained with mouse
OA and 6 patients with RA.
J.-i. Kan et al. / Allergology International 65 (2016) S11eS16S14of IL-17A is 2 pg/mL (Cat# 433914). Histamine release from MCs
were measured using a histamine enzyme immunoassay (EIA) kit
(Immunotech, MBL, Nagano, Japan).
Statistical analysis
The differences in the numbers of synovial MCs, IL-17Aþ MCs
and IL-17Aþ cells, and the percentage of IL-17AþMCs among all the
MCs and among all the IL-17Aþ cells between patients with OA and
RA were evaluated using the ManneWhitney U test. The differ-
ences between two or three independent in vitro experiments were
analyzed using the ManneWhitney U test. A P value <0.05 was
considered signiﬁcant.
Results
To investigate whether MCs in the synovium from patients with
RA express IL-17A as previously reported,11,12,17 we performed dual
staining of synovium samples using anti-IL-17A Ab and anti-
tryptase mAb and compared the expression of IL-17A in synovial
MCs between patients with OA (Fig. 1A-c) and RA (Fig. 1B-c). The
numbers of MCs (tryptaseþ cells: green cells in Fig. 1A-a, B-a) were
not signiﬁcantly different in the synovium from the patients with
OA (median, 89/mm2; inter-quartile range [IQR], 23e209/mm2)
and patients with RA (median, 79/mm2; IQR, 53e104/mm2;
Fig. 2A). The number of IL-17Aþ MCs (median, 16/mm2; IQR, 2e41/
mm2, Fig. 2B) and the percentage of IL-17Aþ MCs in all the MCs in
synovium from patients with RA (yellow cells in Fig. 1B-c, median,
13.6%; IQR, 6.5%e53.1%, Fig. 2D) were also not signiﬁcantly higher
than in those from patients with OA (median, 54/mm2; IQR,
13e119/mm2, Fig. 2B and median, 45.1%; IQR, 7.6%e78.6%, Fig. 2D,
respectively). The number of IL-17Aþ cells and the percentage of IL-Fig. 2. A comparison of the numbers of MCs (A), the numbers of IL-17Aþ MCs (B), the numb
percentage of IL-17Aþ MCs among all the IL-17Aþ cells (E) in synovia from OA patients (ope
median and inter-quartile range. N.S., not signiﬁcant.17Aþ MCs among all the IL-17Aþ cells in synovium from patients
with RA and OA were comparable between the groups (Fig. 2C, E).
To investigate the responsiveness of cultured synovium-derived
MCs from OA patients through Fc 3RI and FcgRI, MCs were activated
with IgE plus anti-IgE and F(ab0)2aFcgRI plus gF(ab0)2amF(ab0)2,
respectively. Using a real-time RT-PCR analysis, IL-17A mRNA was
under detection limit in 2 of the OA patients and 2 of the RA pa-
tients. Following the aggregation of Fc 3RI, a marginable level of IL-
17AmRNAwas detected in theMCs of synovial tissues from 2 of the
2 patients with OA and 0 of the 2 patients with RA (data not
shown). As can be seen in Figure 3, a small amount of IL-17A was
detected in the supernatants from the MCs cultured for 6 h without
any stimulation. However, the levels of IL-17A were not increased
by the aggregation of Fc 3RI or FcgRI (Fig. 3A, B). Furthermore, we
examined whether MCs rapidly release IL-17A following the ag-
gregation of Fc 3RI. IgE-sensitized synovium-derived cultured mast
cells from patients with RA (n ¼ 2 donors) or OA (n ¼ 3 donors)
were incubated with 0.1, 1.0, and 10 mg/mL of anti-IgE for 30min for
IL-17A and histamine assays. Although histamine was released in a
concentration-dependent manner in response to anti-IgE, we failed
to observe the rapid release of IL-17A from synovial MCs (data not
shown). Next, we monitored IL-17A production from cultured
synovium-derived MCs in response to aggregated IgG. IL-17A pro-
duction was not induced by either aggregated IgG or monomeric
IgG (Fig. 3C). IL-33 alone did not induced IL-17A production in
cultured synovium-derived MCs from OA and RA patients (Fig. 3D).
In this series of experiments, the amounts of IL-17A released from
the MCs of RA patients were signiﬁcantly higher than those
released from the MCs of OA patients (at 0 and 10 ng/mL of IL-33;
P < 0.01). IL-33 did not enhance Fc 3RI-, and aggregated IgG-
mediated IL-17A production in cultured synovium-derived MCs
from OA patients (Fig. 3E). As a positive control, we measured theers of IL-17Aþ cells (C), the percentage of IL-17Aþ MCs among all the MCs (D), and the
n circles, n ¼ 6) and from RA patients (closed circles, n ¼ 6). Data are expressed as the
Fig. 3. IL-17A production from cultured synovium-derived MC following IgE- and IgG-dependent stimulation. (A) IgE-sensitized MCs from patients with OA (white bars, n ¼ 4
donors) or from patients with RA (black bars, n ¼ 4 donors) were incubated with anti-IgE for 6 h. (B) MCs from patients with OA (n ¼ 4 donors) were incubated with 1 mg/ml of
F(ab0)2aFcgRI (black bars) or F(ab0)2mIgG1 (white bars) for 30 min and were then stimulated with gF(ab0)2amF(ab0)2 for 6 h. (C) MCs from patients with OA (n ¼ 6 donors) were
stimulated with monomeric IgG or aggregated IgG for 6 h. (D) MCs from patients with OA (white bars, n ¼ 7 donors) and from patients with RA (black bars, n ¼ 4 donors) were
stimulated with IL-33 for 6 h. (E, F) MCs from patients with OA (n ¼ 5e6 donors) were stimulated with anti-Fc 3RI mAb (CRA1), monomeric IgG or aggregated IgG in the presence or
absence of IL-33 for 6 h for IL-17A (E) and IL-8 assays (F). The white, hatched, and black bars show 0, 10, and 30 ng/ml of IL-33. The data are shown as the mean ± SEM. *P < 0.05,
**P < 0.01.
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monomeric IgG, or aggregated IgG in the presence or absence of IL-
33. The MCs produced 5.6 and 1.9 ng/ml of IL-8 in response to anti-
Fc 3RI mAb and aggregated IgG, respectively. The aggregated IgG-
induced production of IL-8 from MCs was signiﬁcantly upregu-
lated by 30 ng/mL of IL-33 (P < 0.05, Fig. 3F).
Since human cord-blood derived cultured MCs reportedly pro-
duce IL-17A upon stimulation with TNF-a, C5a, and LPS, we inves-
tigated the production of IL-17A in cultured synovium-derived MCs
upon these stimuli. However, these stimuli did not induce IL-17A
production (Fig. 4A). As a positive control, we monitored IL-8
production in the same experiments and found that LPS, and IL-
23 plus IL-1b induced signiﬁcant amounts of IL-8 production
(Fig. 4B, P < 0.05).Fig. 4. IL-17A (A) and IL-8 production (B) from cultured synovium-derived MC following vari
a, C5a, LPS, or IL-23 plus IL-1b for 24 h. IL-17 levels were under the detection limit in 2 donor
IL-8 production are shown as the mean ± SEM. *P < 0.05.Discussion
Synovial MCs from patients with either OA or RA expressed IL-
17A, but the frequencies of the expression varied depending on
the donors. The number of IL-17Aþ MCs and the percentage of IL-
17Aþ cells among all the IL-17Aþ cells in the synovium from pa-
tients with RA were not signiﬁcantly higher than those from pa-
tients with OA. This ﬁnding agrees with a previous report by van
Baarsen et al.12 who reported that a signiﬁcant increase in IL-17Aþ
cells (mainly T cells) in the synovium of RA tissue, compared with
noninﬂamed control tissue. However, the expression of IL-17A in
the synovium was similar between RA and OA, and was highly
variable among individual patients, suggesting that heterogeneity
may explain the nonresponse to anti-IL-17 therapy in patients withous stimulations. MCs from patients with OA (n ¼ 3 donors) were stimulated with TNF-
s out of 3 donors. The data of IL-17A production from one donor are shown. The data of
J.-i. Kan et al. / Allergology International 65 (2016) S11eS16S16RA.12 Reportedly, the percentage of IL-17Aþ MCs among all the IL-
17Aþ cells in the synovium differed remarkably: Hueber et al.11
reported that MCs accounted for more than 90% of all the IL-17Aþ
cells. However, we found that among all the IL-17Aþ cells in
synovium samples from patients with OA and RA, 26% and 8% were
MCs, respectively, which is in agreement with the ﬁndings of
Noordenbos et al.'s report.17
Although human cord-blood derived cultured MCs reportedly
produce large amounts of IL-17A (500e800 pg/mL) upon stimula-
tion with TNF-a, IgG complexes, C5a and LPS,11 we were not able to
ﬁnd IL-17A production in cultured synovium-derived MCs using
these stimuli and the same stimulating conditions such as incu-
bation time and stimulus concentration. We did not observe the
upregulation of IL-17A mRNA in cord blood derived-cultured MCs
and peripheral blood derived-cultured MCs using a DNA chip
analysis (data not shown). In synovium and skin samples from
patients with psoriasis, the expression of IL17A in MCs was
reportedly upregulated and the stimulation of MCs with IL-23 plus
IL-1b induced extracellular trap formation to release IL-17A.17,18
Th17 cell differentiation is induced by IL-23 plus IL-1b or by
transforming growth factor-b and IL-6 in the presence of IL-21 or IL-
23, leading to the expression of retinoic acid-related orphan re-
ceptor c. However, we failed to observe the release of IL-17A from
synovial MCs upon IL-23 plus IL-1b stimulation. The question of
whether the long term culture of MCs with IL-23 plus IL-1b induces
phenotypic changes in IL-17A expressing MCs will require further
investigation. We also conﬁrmed that MCs did not rapidly release
IL-17A following the aggregation of Fc 3RI, suggesting that IL-17A
was not stored in the granules or that the levels of IL-17A were
very low, if IL-17A was indeed stored in the granules.
MCs (106 cells/ml) release small amounts of IL-17A (10e20 pg/
ml) without any stimulation. The spontaneous release of IL-17 from
3 out of 22 patients with OA was under the detection limit of the
ELISA. Furthermore, the common stimuli of MCs did not enhance
IL-17A production. The frequencies of IL-17Aþ MCs were not
signiﬁcantly increased in synovium samples from RA patients
compared with OA patients. Therefore, synovial MCs might not be a
main source of IL-17A in RA.
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